

# Chemical biological dissection of Ca<sup>2+</sup> entry through Ca<sup>2+</sup> channels

<https://www.neurodegenerationresearch.eu/survey/chemical-biological-dissection-of-ca2-entry-through-ca2-channels/>

## Principal Investigators

DICK, IVY E

## Institution

UNIVERSITY OF MARYLAND BALTIMORE

## Contact information of lead PI

### Country

USA

## Title of project or programme

Chemical biological dissection of Ca<sup>2+</sup> entry through Ca<sup>2+</sup> channels

## Source of funding information

NIH (NINDS)

## Total sum awarded (Euro)

€ 1,227,447.71

## Start date of award

01/08/2016

## Total duration of award in years

1

## The project/programme is most relevant to:

Parkinson's disease & PD-related disorders

## Keywords

### Research Abstract

DESCRIPTION (provided by applicant): One type of voltage-activated Ca<sup>2+</sup>-permeable ion channel, known as CaV1.3, is emerging as a preeminent Ca<sup>2+</sup> entry pathway into neurons residing at the epicenter of brain rhythmicity and neurodegenerative disease. The lower transmembrane voltages required to open CaV1.3 allow these channels to contribute importantly to pacemaking and subthreshold voltage fluctuations. CaV1.3 channels thus

constitute a dominant Ca<sup>2+</sup> entry module into many neurons undergoing oscillatory and subthreshold activity. Nowhere is this Ca<sup>2+</sup> entry function more salient than in substantia nigral neurons, where CaV1.3 channels furnish the lion's share of Ca<sup>2+</sup> entry, while driving rapid pacemaking essential for movement control. Notably, degeneration of substantia nigral neurons is central to Parkinson's disease (PD), and intracellular Ca<sup>2+</sup> dysregulation and overload are crucial to PD pathogenesis. Accordingly, a highly promising avenue for novel PD therapeutics involves the burgeoning search for small molecules that selectively inhibit the opening of CaV1.3 channels. Yet, comparatively little is known about the mechanisms controlling the open probability PO of CaV1.3 channels. Ongoing small-molecule screens thereby rely on rank empiricism, largely bereft of known channel interfaces to which drug binding would likely alter opening. Multiplying the challenge is the recent discovery that CaV1.3 channels are not monolithic, but comprised of numerous RNA-edited and splice variants, each with potentially distinct effects on the open probability PO of channels. The mechanism underlying variant-related PO modulation is currently obscure. Additionally, GPCR-mediated changes in the plasmalemmal lipid PIP<sub>2</sub> powerfully regulates PO, but it is unknown how this occurs, and how it relates to edited/splice variation. Together, the mechanistic void relating to these two systems precludes quantitative understanding of how Ca<sup>2+</sup> entry through these channels contributes to pathogenesis, and obscures the path to rational small-molecule screens for CaV1.3 modulators. Yet, forward progress has proven difficult by traditional means alone. This project thus proposes to clarify CaV1.3 PO modulation by melding electrophysiology with novel chemical-biological and live-cell FRET tools. Overall, this proposal promises elegant clarification, simplification, an unification of seemingly diverse mechanisms of CaV1.3 PO modulation; identification of channel interfaces that could be targeted for discovery of small-molecule PO modulators; and new chemical-biological and FRET-based tools of wide applicability.

### **Lay Summary**

**PUBLIC HEALTH RELEVANCE:** CaV1.3 calcium channels are emerging as a preeminent Ca<sup>2+</sup> entry pathway into neurons residing at the epicenter of brain rhythmicity and neurodegenerative disease. Accordingly, understanding how the opening of these channels is modulated, and discovering small molecules that selectively inhibit such opening, both present as crucial dimensions for novel therapeutics. Here, we will devise chemical-biological and live-cell FRET-based tools to clarify the sought-after modulatory mechanisms and identify channel interfaces that could be targeted for small-molecule drug discovery.

### **Further information available at:**

#### **Types:**

Investments > €500k

#### **Member States:**

United States of America

#### **Diseases:**

Parkinson's disease & PD-related disorders

#### **Years:**

2016

#### **Database Categories:**

N/A

**Database Tags:**

N/A